Cargando…

Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans

Fungal populations are commonly found in natural environments and present enormous health care challenges, due to increased resistance to antifungal agents. Paeonol exhibits antifungal activities; nevertheless, the antifungal and antibiofilm activities of paeonol against Candida albicans and Cryptoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Weidong, Li, Xinchen, Liu, Qiming, Lu, Jiaxing, Wang, Ting, Zhang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163411/
https://www.ncbi.nlm.nih.gov/pubmed/35669114
http://dx.doi.org/10.3389/fcimb.2022.884793
_version_ 1784719914849796096
author Qian, Weidong
Li, Xinchen
Liu, Qiming
Lu, Jiaxing
Wang, Ting
Zhang, Qian
author_facet Qian, Weidong
Li, Xinchen
Liu, Qiming
Lu, Jiaxing
Wang, Ting
Zhang, Qian
author_sort Qian, Weidong
collection PubMed
description Fungal populations are commonly found in natural environments and present enormous health care challenges, due to increased resistance to antifungal agents. Paeonol exhibits antifungal activities; nevertheless, the antifungal and antibiofilm activities of paeonol against Candida albicans and Cryptococcus neoformans remain largely unexplored. Here, we aimed to evaluate the antifungal and antibiofilm activities of paeonol against C. albicans and/or C. neoformans (i.e., against mono- or dual-species). The minimum inhibitory concentrations (MICs) of paeonol for mono-species comprising C. albicans or C. neoformans were 250 μg ml(−1), whereas the MIC values of paeonol for dual-species were 500 μg ml(−1). Paeonol disrupted cell membrane integrity and increased the influx of gatifloxacin into cells of mono- and dual-species cells, indicating an antifungal mode of action. Moreover, paeonol at 8 times the MIC damaged mono- and dual-species cells within C. albicans and C. neoformans biofilms, as it did planktonic cells. In particular, at 4 and 8 mg ml(−1), paeonol efficiently dispersed preformed 48-h biofilms formed by mono- and dual-species cells, respectively. Paeonol inhibited effectively the yeast-to-hyphal-form transition of C. albicans and impaired capsule and melanin production of C. neoformans. The addition of 10 MIC paeonol to the medium did not shorten the lifespan of C. elegans, and 2 MIC paeonol could effectively protect the growth of C. albicans and C. neoformans-infected C. elegans. Furthermore, RNA sequencing was employed to examine the transcript profiling of C. albicans and C. neoformans biofilm cells in response to 1/2 MIC paeonol. RNA sequencing data revealed that paeonol treatment impaired biofilm formation of C. albicans by presumably downregulating the expression level of initial filamentation, adhesion, and growth-related genes, as well as biofilm biosynthesis genes, whereas paeonol inhibited biofilm formation of C. neoformans by presumably upregulating the expression level of ergosterol biosynthesis-related genes. Together, the findings of this study indicate that paeonol can be explored as a candidate antifungal agent for combating serious single and mixed infections caused by C. albicans and C. neoformans.
format Online
Article
Text
id pubmed-9163411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91634112022-06-05 Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans Qian, Weidong Li, Xinchen Liu, Qiming Lu, Jiaxing Wang, Ting Zhang, Qian Front Cell Infect Microbiol Cellular and Infection Microbiology Fungal populations are commonly found in natural environments and present enormous health care challenges, due to increased resistance to antifungal agents. Paeonol exhibits antifungal activities; nevertheless, the antifungal and antibiofilm activities of paeonol against Candida albicans and Cryptococcus neoformans remain largely unexplored. Here, we aimed to evaluate the antifungal and antibiofilm activities of paeonol against C. albicans and/or C. neoformans (i.e., against mono- or dual-species). The minimum inhibitory concentrations (MICs) of paeonol for mono-species comprising C. albicans or C. neoformans were 250 μg ml(−1), whereas the MIC values of paeonol for dual-species were 500 μg ml(−1). Paeonol disrupted cell membrane integrity and increased the influx of gatifloxacin into cells of mono- and dual-species cells, indicating an antifungal mode of action. Moreover, paeonol at 8 times the MIC damaged mono- and dual-species cells within C. albicans and C. neoformans biofilms, as it did planktonic cells. In particular, at 4 and 8 mg ml(−1), paeonol efficiently dispersed preformed 48-h biofilms formed by mono- and dual-species cells, respectively. Paeonol inhibited effectively the yeast-to-hyphal-form transition of C. albicans and impaired capsule and melanin production of C. neoformans. The addition of 10 MIC paeonol to the medium did not shorten the lifespan of C. elegans, and 2 MIC paeonol could effectively protect the growth of C. albicans and C. neoformans-infected C. elegans. Furthermore, RNA sequencing was employed to examine the transcript profiling of C. albicans and C. neoformans biofilm cells in response to 1/2 MIC paeonol. RNA sequencing data revealed that paeonol treatment impaired biofilm formation of C. albicans by presumably downregulating the expression level of initial filamentation, adhesion, and growth-related genes, as well as biofilm biosynthesis genes, whereas paeonol inhibited biofilm formation of C. neoformans by presumably upregulating the expression level of ergosterol biosynthesis-related genes. Together, the findings of this study indicate that paeonol can be explored as a candidate antifungal agent for combating serious single and mixed infections caused by C. albicans and C. neoformans. Frontiers Media S.A. 2022-05-20 /pmc/articles/PMC9163411/ /pubmed/35669114 http://dx.doi.org/10.3389/fcimb.2022.884793 Text en Copyright © 2022 Qian, Li, Liu, Lu, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Qian, Weidong
Li, Xinchen
Liu, Qiming
Lu, Jiaxing
Wang, Ting
Zhang, Qian
Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title_full Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title_fullStr Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title_full_unstemmed Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title_short Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
title_sort antifungal and antibiofilm efficacy of paeonol treatment against biofilms comprising candida albicans and/or cryptococcus neoformans
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163411/
https://www.ncbi.nlm.nih.gov/pubmed/35669114
http://dx.doi.org/10.3389/fcimb.2022.884793
work_keys_str_mv AT qianweidong antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans
AT lixinchen antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans
AT liuqiming antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans
AT lujiaxing antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans
AT wangting antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans
AT zhangqian antifungalandantibiofilmefficacyofpaeonoltreatmentagainstbiofilmscomprisingcandidaalbicansandorcryptococcusneoformans